Pfizer COVID-19 Seems Promising But What's Next? : Short Wave Interim results are in from a large trial of an experimental COVID-19 vaccine. Drug maker Pfizer, working with German company BioNTech, says its vaccine appears to be working really well--it was found to be more than 90 percent effective. Today on Short Wave, host Maddie Sofia talks to NPR science correspondent Joe Palca about what that efficacy number means, details of the study and what more information about the vaccine researchers are awaiting.

Reach the show by emailing us at shortwave@npr.org.
NPR logo

The COVID-19 Vaccine Trial Results: What They Mean, What Comes Next

  • Download
  • <iframe src="https://www.npr.org/player/embed/934164473/934331017" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
The COVID-19 Vaccine Trial Results: What They Mean, What Comes Next

The COVID-19 Vaccine Trial Results: What They Mean, What Comes Next

The COVID-19 Vaccine Trial Results: What They Mean, What Comes Next

  • Download
  • <iframe src="https://www.npr.org/player/embed/934164473/934331017" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

This taken in Oct. 2020 and provided by Pfizer shows part of a "freezer farm," a football field-sized facility for storing finished COVID-19 vaccines, in Puurs, Belgium. AP hide caption

toggle caption
AP

Interim results are in from a large trial of an experimental COVID-19 vaccine. Drug maker Pfizer, working with German company BioNTech, says its vaccine appears to be working really well--it was found to be more than 90 percent effective. Today on Short Wave, host Maddie Sofia talks to NPR science correspondent Joe Palca about what that efficacy number means, details of the study and what more information about the vaccine researchers are awaiting.

This episode was produced by Thomas Lu, edited by Gisele Grayson, and fact-checked by Ariela Zebede.